Search - tctmd.com

Displaying 1 - 20 of 405

Sort: Relevancy | Date

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

Shelley Wood

December 29, 2016

News Daily News

Objective Tests of Frailty Surpass ‘Eyeballing’ in Patients With Valvular Disease

Caitlin E. Cox

December 20, 2016

News Daily News

Women More Likely to be Alive 1 Year After TAVR: STS/ACC TVT Registry

Michael O'Riordan

December 19, 2016

News Daily News

Conflict Persists Between Guidelines and Practice When It Comes to Treating CAD in TAVR Candidates

Todd Neale

December 08, 2016

News Daily News

PFO and Migraine? New Study Zeros in on Atrial Septal Aneurysms

Shelley Wood

December 08, 2016

News Daily News

Believe It: Mitral Valve Repair Beats Replacement for Severe Regurgitation, Registry Shows

Shelley Wood

December 05, 2016

News Daily News

More A-fib, No Drop in Stroke or Death With Surgical Left Atrial Appendage Exclusion

Todd Neale

December 05, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2016

Shelley Wood

November 30, 2016

News Daily News

Intracardiac Shunts After TAVR: Rare but Potentially Lethal

Todd Neale

November 28, 2016

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Shelley Wood

November 28, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Industry News

Initial Results of LAA Closure Device for Stroke Prevention in Patients with Atrial Fibrillation Demonstrate Device Safety and Low Rates of Major Adverse Events

November 02, 2016

News Conference News TCT 2016

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

Yael L. Maxwell

November 02, 2016

Presentation TCT 2016

Cryptogenic Stroke, Thrombophilia, VTE, and PFO: Do We Know What To Do?

Presenter: Eustaquio Maria Onorato, Richard Smalling, Robert J. Sommer

November 01, 2016

Presentation TCT 2016

The REDUCE Trial: Will It Be Positive and What Will We Learn?

Presenter: Eustaquio Maria Onorato, Richard Smalling, John F. Rhodes

November 01, 2016

Presentation TCT 2016

What Should Be the Next Series of Clinical Trials in PFO Closure?

Presenter: Eustaquio Maria Onorato, Richard Smalling, John D. Carroll

November 01, 2016

Presentation TCT 2016

The Neurologist as the Gatekeeper of PFO Closure in the US: What is Cryptogenic Stroke and When Do Neurologists Think PFO Closure Is Needed?

Presenter: Eustaquio Maria Onorato, Richard Smalling, David E. Thaler

November 01, 2016

Presentation TCT 2016

Anticipating FDA approval of the Amplatzer PFO Occluder: Indications, Rational Dispersion of Technology, and Post-Approval Studies

Presenter: Eustaquio Maria Onorato, Richard Smalling

November 01, 2016

Presentation TCT 2016

Building a Successful PFO Closure Program

Presenter: John D. Carroll, Christian Spies

November 01, 2016

Advertisement

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

TCTMD’s Top 10 Most Popular News and Features for 2016

Objective Tests of Frailty Surpass ‘Eyeballing’ in Patients With Valvular Disease

Women More Likely to be Alive 1 Year After TAVR: STS/ACC TVT Registry

Conflict Persists Between Guidelines and Practice When It Comes to Treating CAD in TAVR Candidates

PFO and Migraine? New Study Zeros in on Atrial Septal Aneurysms

Believe It: Mitral Valve Repair Beats Replacement for Severe Regurgitation, Registry Shows

More A-fib, No Drop in Stroke or Death With Surgical Left Atrial Appendage Exclusion

TCTMD’s Top 10 Most Popular Stories for November 2016

Intracardiac Shunts After TAVR: Rare but Potentially Lethal

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Initial Results of LAA Closure Device for Stroke Prevention in Patients with Atrial Fibrillation Demonstrate Device Safety and Low Rates of Major Adverse Events

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

Cryptogenic Stroke, Thrombophilia, VTE, and PFO: Do We Know What To Do?

The REDUCE Trial: Will It Be Positive and What Will We Learn?

What Should Be the Next Series of Clinical Trials in PFO Closure?

The Neurologist as the Gatekeeper of PFO Closure in the US: What is Cryptogenic Stroke and When Do Neurologists Think PFO Closure Is Needed?

Anticipating FDA approval of the Amplatzer PFO Occluder: Indications, Rational Dispersion of Technology, and Post-Approval Studies

Building a Successful PFO Closure Program

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content